Elemental impurities contained in pharmaceutical products are getting more and more attention due to their potential harm on patient health and the impact on drug shelf time and effectiveness. The United States Pharmacopeia (USP) has been continuously developing new guidelines in recent years to replace the over 100-year-old USP<231>. The Heavy Metal Limit Test procedure using colorimetric test method in the USP<231> is no longer adequate for quantitation of elements at toxicologically relevant levels. The new USP guidelines for elemental impurities has been implemented since 1 January 2018. After harmonized to ICH Q3D, USP<232> specifies the impurities limits for 24 elements based on their toxicity. USP<233> recommends two modern measuring techniques (i.e. ICP-OES and ICP-MS) and the measuring and validation procedures. ICP-MS is indisputably considered as the best technique for determination of the 24 elements at trace levels in pharmaceutical products because of its superior sensitivity and simultaneous analysis capability of multi-elements. This application news describes the ICPMS procedure and results for analysis of 23 elemental impurities in three pharmaceutical products following USP<232>/ <233> criteria on ICPMS-2030.